Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
GH Research (GHRS)
NASDAQ:GHRS
GH Research (GHRS) Stock Price & Analysis
121 Followers
GHRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.05 - $14.64
Previous Close$10.51
Volume19.95K
Average Volume (3M)123.66K
Market Cap
$587.92M
Enterprise Value$441.84M
Total Cash (Recent Filing)$105.94M
Total Debt (Recent Filing)$974.00K
Price to Earnings (P/E)-15.4
Beta0.80
Next Earnings
May 15, 2024EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding52,028,145
10 Day Avg. Volume72,411
30 Day Avg. Volume123,658
Standard Deviation0.18
R-Squared0.06
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.49
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.26K
Forecast
1Y Price Target
$39.50Price Target Upside275.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
GH Research News
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressGH001's progression in a Phase 2b trial for treatment resistant depression is expected to significantly mitigate risks associated with the program, with strong recruitment indicating a timely completion and anticipation of positive top-line data.
Financial StabilityThe company is in a robust financial position with a cash balance sufficient to fund operations well into the future, highlighting a stable runway for continued research and development activities.
Intellectual PropertyThe granting of a new patent by the European Patent Office strengthens the company's intellectual property portfolio, signaling a competitive edge and protection for its innovative treatments.
Bears Say
Clinical Trial ProgressGH needs to assess the impact of measures implemented to improve recruitment for the Phase 2 trial in bipolar II disorder before providing an updated timeline.
Clinical Trial RecruitmentRecruitment for Phase 2a trials in postpartum depression and bipolar depression has been slower than expected, impacted by the closure of CRO clinical sites.
Stock ValuationAnalysts lower the risk-adjusted, DCF-derived price target to $39 due to a one-year shift in launch expectations and a new assumption for an equity financing.
---
Ownership Overview
0.00%
Insiders
4.33% Mutual Funds
0.24% Other Institutional Investors
95.43% Public Companies and
Individual Investors
GHRS FAQ
What was GH Research’s price range in the past 12 months?
GH Research lowest stock price was $5.05 and its highest was $14.64 in the past 12 months.
What is GH Research’s market cap?
Currently, no data Available
When is GH Research’s upcoming earnings report date?
GH Research’s upcoming earnings report date is May 15, 2024 which is in 17 days.
How were GH Research’s earnings last quarter?
GH Research released its earnings results on Feb 29, 2024. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.204 by -$0.006.
Is GH Research overvalued?
According to Wall Street analysts GH Research’s price is currently Undervalued.
Does GH Research pay dividends?
GH Research does not currently pay dividends.
What is GH Research’s EPS estimate?
GH Research’s EPS estimate is -$0.22.
How many shares outstanding does GH Research have?
GH Research has 52,028,145 shares outstanding.
What happened to GH Research’s price movement after its last earnings report?
GH Research reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.204. Following the earnings report the stock price went up 7.898%.
Which hedge fund is a major shareholder of GH Research?
Among the largest hedge funds holding GH Research’s share is RA Capital Management. It holds GH Research’s shares valued at 32M.
---
GH Research Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.50 (275.83% Upside)
$39.50 (275.83% Upside)
Blogger Sentiment
Bullish
GHRS Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.86%
12-Months-Change
Fundamentals
Return on Equity
-15.18%
Trailing 12-Months
Asset Growth
-11.03%
Trailing 12-Months
Company Description
GH Research
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
---
GHRS Stock 12 Months Forecast
Average Price Target
$39.50
▲(275.83% Upside)
Technical Analysis
Best Analysts Covering GHRS
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+8.10%
reiterated a buy rating 2 months ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +8.10% per trade.
---